Nasal Vaccine: A Possible Alternative to Traditional Injections

Intranasal vaccines offer an alternative way of vaccine administration compared to traditional injections. These vaccines are sprayed into the nasal cavity instead of being injected into the muscle or skin. Delivery through the nasal route aims to induce protective immunity directly at the entry point of many respiratory pathogens.

How do Nasal Vaccine Work?

Intranasal vaccines work through the innate and adaptive immune responses in the nasal mucosa and upper respiratory tract. When administered into the nose, Nasal Vaccine antigen is presented to immune cells located in the nasal-associated lymphoid tissue (NALT). This early interaction triggers both humoral and cellular immune responses.

Antibodies known as immunoglobulin A (IgA) are produced locally in the nasal mucosa providing the first line of defense. IgA antibodies can prevent viruses and bacteria from attaching to and entering the cells of the respiratory epithelium. Additionally, the interaction in the NALT stimulates B and T cells which travel through the lymphatic system and blood to provide wider immunity throughout the body. Memory B and T cells are also generated to recognize future exposures to the pathogen.

Types of Vaccines Being Developed for Nasal Delivery

Several types of vaccines are currently under development for nasal administration to provide protection against respiratory infections:

Influenza Vaccines: Nasal influenza vaccines aims to induce mucosal immunity directly in the respiratory tract providing stronger protection than intramuscular flu shots. Recent clinical trials have demonstrated efficacy comparable to traditional flu shots. If approved, nasal flu vaccines could offer an easier alternative without use of needles.

RSV Vaccines: Respiratory syncytial virus (RSV) is a common cause of pneumonia in infants and the elderly. Nasally administered RSV vaccines are being tested to induce protective immunity in the airways. Early studies show promise in generating both local and systemic antibody responses in animal models.

COVID-19 Vaccines: With SARS-CoV-2 primarily infecting through the upper respiratory tract, intranasal COVID vaccines are being explored. Nasal Vaccine hope localized mucosal immunity in the nose and throat could block viral entry and reduce transmission in addition to preventing illness. Ongoing clinical trials will reveal if this approach is viable.

Potential Advantages of Nasal Vaccine

Some key potential benefits of intranasal vaccines over intramuscular injections include:

- Induction of mucosal immunity: Nasal delivery aims to generate protective antibodies directly in the respiratory tract which may block pathogens from establishing infection.

- Prevention of infection and transmission: Local immune responses in the nasal cavity and lungs may not only protect the vaccinated individual from disease but also prevent asymptomatic carriage and onward transmission to others.

- Needle-free administration: Nasal spray vaccines avoid use of hypodermic needles eliminating pain and the biohazard risks involved in disposing used needles. This could increase vaccine acceptance.

- Thermostability: Most nasal spray vaccines are formulated to remain stable even without refrigeration making them easier to transport and distribute globally especially in lowresource settings.

- Self-administration: The non-invasive nature of nasal sprays will allow self-or minimal healthcare worker-administration improving access.

Challenges of Developing Effective Intranasal vaccines

However, nasal delivery of vaccines is not without scientific and technical challenges:

- Lower immune responses for some pathogens: Systemic immunity after nasal administration may be inferior compared to intramuscular routes depending on the pathogen. Adjuvants may help boost the immune response.

- Rapid clearance from nasal cavity: The vaccine needs to remain in contact with nasal mucosa time enough for uptake by immune cells before being cleared by mucociliary clearance within 30 minutes on average.

- Interference from existing infections/inflammation: Concurrent viral infections or allergies in the nose may interfere with vaccine effectiveness by competing for immune cells and affecting permeability of the nasal epithelium.

- Variability in delivery method: Ensuring consistent droplet sizes, volumes are delivered completely and bilaterally to both nostrils is important but challenging with current spray delivery devices. Improved delivery systems need to be developed.

Overall, Nasal Vaccine offer potential advantages of safety, convenience and ability to induce protective immunity directly at the primary infection site. With continued progress on addressing formulation and delivery hurdles, some intranasal vaccines may become available commercially in the coming years to help control seasonal and pandemic respiratory infections. Further research is still ongoing to optimize the design of new generation intranasal vaccines.

Get More Insights On Nasal Vaccines 

 

Unlock More Insights—Explore the Report in the Language You Prefer

French German Italian RussianJapaneseChinese Korean Portuguese
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)